Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression. Use of traditional antidepressants is often limited by the short prognosis associated with advanced cancer. We present the case of a patient with neuropathic pain from advanced cancer and severe depression that responded dramatically to an intravenous infusion of ketamine resulting in decreased pain and resolution of severe depression symptoms.
Get full access to this article
View all access options for this article.
References
1.
LossignolDA, Obiols-PortisM, BodyJJ: Successful use of ketamine for intractable cancer pain. Support Care Cancer, 2005; 13:188–193.
2.
Stefanczyk-SapiehaL, OneschukD, DemasM: Intravenous ketamine “burst” for refractory depression in a patient with advanced cancer. J Palliat Med, 2008; 11:1268–1271.
3.
JacobsenPB, JimHS: Psychosocial interventions for anxiety and depression in adult cancer patients: Achievements and challenges. CA Cancer J Clin, 2008; 58:214–230.
4.
SwarmRA, AbernethyAP, AnghelescuDL, et al.: Adult cancer pain. J Natl Compr Cancer Netw, 2013; 11:992–1022.
5.
aan het RotM, CollinsKA, MurroughJW, et al.: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 2010; 67:139–145.
6.
BermanRM, CappielloA, AnandA, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000; 47:351–354.
7.
FondG, LoundouA, RabuC, et al.: Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology, 2014; 231:3663–3676.
8.
McGirrA, BerlimMT, BondDJ, et al.: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med, 2015; 45:693–704.
9.
MurroughJW, PerezAM, PillemerS, et al.: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 2013; 74:250–256.
10.
RasmussenKG, LineberryTW, GalardyCW, et al.: Serial infusions of low-dose ketamine for major depression. J Psychopharmacol, 2013; 27:444–450.
BadrinathS, AvramovMN, ShadrickM, et al.: The use of a ketamine-propofol combination during monitored anesthesia care. Anesth analg, 2000; 90:858–862.
13.
BellR, EcclestonC, KalsoE: Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev, 2003:CD003351.
14.
GofritON, LeiboviciD, ShemerJ, et al.: Ketamine in the field: The use of ketamine for induction of anaesthesia before intubation in injured patients in the field. Injury, 1997; 28:41–43.
15.
GraudinsA, MeekR, Egerton-WarburtonD, et al.: The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: A randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med, 2015; 65:248.e1–254.e1.
16.
SarmaVJ: Use of ketamine in acute severe asthma. Acta Anaesthesiol Scand, 1992; 36:106–107.
17.
SinnerB, GrafBM: Ketamine. In: SchüttlerJ, SchwildenH (eds): Modern Anesthetics. Handbook of Experimental Pharmacology. Springer: Berlin, Heidelberg, 2008, p. 182
18.
EsinE, YalcinS: Neuropathic cancer pain: What we are dealing with? How to manage it?. OncoTargets Ther, 2014; 7:599–618.
ZgaiaAO, IrimieA, SandescD, et al.: The role of ketamine in the treatment of chronic cancer pain. Clujul Med, 2015; 88:457–461.
21.
IrwinSA, IglewiczA: Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med, 2010; 13:903–908.
22.
NewportDJ, CarpenterLL, McDonaldWM, et al.: Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry, 2015; 172:950–966.
23.
KudohA, TakahiraY, KatagaiH, TakazawaT: Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg, 2002; 95:114–118, table of contents.
24.
ZarateCAJr., SinghJB, CarlsonPJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006; 63:856–864.
25.
AndersonF, DowningGM, HillJ, et al.: Palliative performance scale (PPS): A new tool. J Palliat Care, 1996; 12:5–11.
26.
OkenMM, CreechRH, TormeyDC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982; 5:649–655.
27.
JangRW, CaraiscosVB, SwamiN, et al.: Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract, 2014; 10:e335–e341.
28.
ZanicottiCG, PerezD, GlueP: Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med, 2012; 15:400–403.
29.
RosensteinDL: Depression and end-of-life care for patients with cancer. Dialogues Clin Neurosci, 2011; 13:101–108.
30.
FairmanN, HirstJ, IrwinS: Clinical Manual of Palliative Care Psychiatry. American Psychiatric Publishing, Arlington, VA, 2016.
31.
KerrCW, DrakeJ, MilchRA, et al.: Effects of methylphenidate on fatigue and depression: A randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage, 2012; 43:68–77.
